Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) have earned an average recommendation of “Hold” from the five brokerages that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is C$23.33.

Several equities research analysts recently commented on VRX shares. TD Securities boosted their target price on Valeant Pharmaceuticals Intl to C$26.00 and gave the stock a “hold” rating in a report on Wednesday, July 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, June 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a C$25.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Monday, June 19th.

Shares of Valeant Pharmaceuticals Intl (TSE VRX) opened at 17.92 on Thursday. Valeant Pharmaceuticals Intl has a 12-month low of $11.20 and a 12-month high of $32.50. The company has a 50 day moving average price of $17.36 and a 200-day moving average price of $17.30. The firm’s market cap is $6.25 billion.

In other news, Director Schutter Richard Urbain De acquired 4,900 shares of the stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of C$14.35 per share, for a total transaction of C$70,315.00. Also, Director John Paulson sold 24,700 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total transaction of C$362,102.00.

TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl Inc (VRX) Given Average Recommendation of “Hold” by Analysts” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/05/valeant-pharmaceuticals-intl-inc-vrx-given-average-recommendation-of-hold-by-analysts.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.